Takeda “announced that LIVTENCITY has been approved by the National Medical Products Administration of China for the treatment of adult patients with post-hematopoietic stem cell transplant or solid organ transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet. LIVTENCITY is the first and only inhibitor of CMV-specific UL97 protein kinase in China for this indication. LIVTENCITY was granted Breakthrough Therapy Designation by China Center for Drug Evaluation in 2021. The NMPA approval is based on the results of the Phase 3 SOLSTICE trial, which evaluated the safety and efficacy of maribavir versus conventional antiviral therapies – ganciclovir, valganciclovir, cidofovir or foscarnet – for the treatment of patients with CMV infection/disease refractory* to prior therapies. In the SOLSTICE trial, LIVTENCITY was superior to conventional therapies at Week 8 for the primary endpoint of confirmed CMV viremia clearancea in post-transplant adults with refractory* CMV infection.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TAK:
- Takeda announces CHMP opinion recommending approval of Hyqvia
- Takeda says FDA approves ADZYNMA
- FDA approves Takeda’s Adzynma for rare inherited blood clotting disorder
- Takeda gets FDA approval of Fruzaqla for previously treated colorectal cancer
- Stifel downgrades Ventyx Biosciences after ‘disappointing’ VTX958 data